Su Y Kim1, Katherine Janeway, Alberto Pappo. 1. Pediatric Oncology Branch National Cancer Institute National Institutes of Health, Bethesda, Maryland 20892, USA. kimsuyou@mail.nih.gov
Abstract
PURPOSE OF REVIEW: Pediatric gastrointestinal stromal tumor is an uncommon tumor, the rarity of which has made both laboratory research studies and clinical management very difficult. As we learn more about this disorder, what is emerging is that this rare cancer is markedly different in children and adults. One of the main biological differences is that pediatric patients lack activating mutations in the oncogenes that drive tumor formation in adults. The natural history of this disease also appears to be more indolent in children than in adults. In this review, we will discuss the differences between children and adults with gastrointestinal stromal tumor and some new potential therapeutic agents. RECENT FINDINGS: This review discusses recent advances and the rationale for several recently identified molecular targets. In addition, we discuss the formation of a clinic at the National Institutes of Health that is dedicated to the study of this rare disorder. SUMMARY: Collaborative efforts are underway to better define the natural history and clinical course of pediatric patients with gastrointestinal stromal tumor. When combined with innovative genomic and molecular studies, these dual approaches will allow for notable advances in this field.
PURPOSE OF REVIEW: Pediatric gastrointestinal stromal tumor is an uncommon tumor, the rarity of which has made both laboratory research studies and clinical management very difficult. As we learn more about this disorder, what is emerging is that this rare cancer is markedly different in children and adults. One of the main biological differences is that pediatric patients lack activating mutations in the oncogenes that drive tumor formation in adults. The natural history of this disease also appears to be more indolent in children than in adults. In this review, we will discuss the differences between children and adults with gastrointestinal stromal tumor and some new potential therapeutic agents. RECENT FINDINGS: This review discusses recent advances and the rationale for several recently identified molecular targets. In addition, we discuss the formation of a clinic at the National Institutes of Health that is dedicated to the study of this rare disorder. SUMMARY: Collaborative efforts are underway to better define the natural history and clinical course of pediatric patients with gastrointestinal stromal tumor. When combined with innovative genomic and molecular studies, these dual approaches will allow for notable advances in this field.
Authors: Sonam Prakash; Lisa Sarran; Nicholas Socci; Ronald P DeMatteo; Jonathan Eisenstat; Alba M Greco; Robert G Maki; Leonard H Wexler; Michael P LaQuaglia; Peter Besmer; Cristina R Antonescu Journal: J Pediatr Hematol Oncol Date: 2005-04 Impact factor: 1.289
Authors: B E Plaat; H Hollema; W M Molenaar; G H Torn Broers; J Pijpe; M F Mastik; H J Hoekstra; E van den Berg; R J Scheper; W T van der Graaf Journal: J Clin Oncol Date: 2000-09-15 Impact factor: 44.544
Authors: S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura Journal: Science Date: 1998-01-23 Impact factor: 47.728
Authors: Katherine A Janeway; Mei-Jun Zhu; Jordi Barretina; Antonio Perez-Atayde; George D Demetri; Jonathan A Fletcher Journal: Int J Cancer Date: 2010-12-01 Impact factor: 7.396
Authors: J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Christopher B Weldon; Arin L Madenci; Sosipatros A Boikos; Katherine A Janeway; Suzanne George; Margaret von Mehren; Alberto S Pappo; Joshua D Schiffman; Jennifer Wright; Jonathan C Trent; Karel Pacak; Constantine A Stratakis; Lee J Helman; Michael P La Quaglia Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: V R Bulusu; J Fullarton; M Leahy; C Morgan; A Rasheed; P Taniere; S Toh; M Verrill; J White; I Judson Journal: Br J Cancer Date: 2013-08-20 Impact factor: 7.640